Instituto Universitario de Tecnologías Biomédicas
Instituto de investigación
University of Belgrade
Belgrado, SerbiaPublicaciones en colaboración con investigadores/as de University of Belgrade (17)
2024
-
Coumarins-lipophilic cations conjugates: Efficient mitocans targeting carbonic anhydrases
Bioorganic Chemistry, Vol. 145
2023
-
Biotinylated selenocyanates: Potent and selective cytostatic agents
Bioorganic Chemistry, Vol. 133
-
Structural, physicochemical and anticancer study of Zn complexes with pyridyl-based thiazolyl-hydrazones
Journal of Molecular Structure, Vol. 1281
2022
-
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors
Frontiers in Pharmacology, Vol. 13
-
Straightforward access to novel mitochondriotropics derived from 2-arylethanol as potent and selective antiproliferative agents
European Journal of Medicinal Chemistry, Vol. 228
-
Study of the anticancer potential of Cd complexes of selenazoyl-hydrazones and their sulfur isosters
European Journal of Medicinal Chemistry, Vol. 238
-
Zn(ii) complexes with thiazolyl-hydrazones: structure, intermolecular interactions, photophysical properties, computational study and anticancer activity
CrystEngComm, Vol. 24, Núm. 29, pp. 5194-5214
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Structural, antioxidant, antiproliferative and in‒silico study of pyridine-based hydrazonyl‒selenazoles and their sulphur isosteres
Journal of Molecular Structure, Vol. 1240
2020
-
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells
Investigational New Drugs, Vol. 38, Núm. 3, pp. 584-598
-
Repurposing old drugs to fight multidrug resistant cancers
Drug Resistance Updates, Vol. 52
2019
2018
-
Selenazolyl-hydrazones as novel selective MAO inhibitors with antiproliferative and antioxidant activities: Experimental and In-silico studies
Frontiers in Chemistry, Vol. 6, Núm. JUL
2017
-
DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells
European Journal of Pharmaceutical Sciences, Vol. 105, pp. 159-168
2016
2012
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544